Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2020

01-06-2020 | Botulinum Toxin | UNM CLINICAL CASE CONFERENCES

Bar None: A Rare Cause of Oropharyngeal Dysphagia

Authors: Vaishnavi Boppana, Karen SantaCruz, Manish Shrestha, Nicholas Volpicelli, Denis McCarthy

Published in: Digestive Diseases and Sciences | Issue 6/2020

Login to get access

Excerpt

A 70-year-old obese male previously diagnosed with inclusion body myositis (IBM) on the basis of a muscle biopsy a year prior to presentation to the gastroenterology clinic with complaints of progressive swallowing difficulties. He described the sensation of food sticking below his Adam’s apple with occasional regurgitation. He also stated that he occasionally experienced choking when swallowing. He noticed that he had to swallow repeatedly to help clear solid food. Furthermore, he complained of drooping of his eyelids. Otherwise he denied any changes in voice, difficulty with speech, trouble with language, neck pain or swelling, or cough. He was a former smoker and used to drink 4–5 beers per week, but quit these one year previously. He had had some baseline difficulty breathing with walking for some time and had experienced heartburn, controlled by taking oral pantoprazole 20 mg twice daily. He had previously undergone a partial uvulectomy about 6–7 years prior for obstructive sleep apnea and more recently had a muscle biopsy that established the diagnosis of IBM. The biopsy findings shown in Figs. 1 and 2 reveal, on H&E staining features of an inflammatory myositis (Fig. 1a): additional special stains (Figs. 1b, 2a, b) demonstrate features characteristic of IBM.
Literature
2.
go back to reference Karpati G, O’Ferrell EK. Sporadic inclusion body myositis; pathogenic considerations. Ann Neurol. 2009;65:7–11.CrossRef Karpati G, O’Ferrell EK. Sporadic inclusion body myositis; pathogenic considerations. Ann Neurol. 2009;65:7–11.CrossRef
3.
go back to reference Oh TH, Brumfield KA, Hoskin TL, Kasperbauer JL, Basford JR. Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome. Am J Phys Med Rehabil. 2008;87:883.CrossRef Oh TH, Brumfield KA, Hoskin TL, Kasperbauer JL, Basford JR. Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome. Am J Phys Med Rehabil. 2008;87:883.CrossRef
4.
go back to reference Cox FM, Verschuuren JJ, Verbist BM, Niks EH, Wintzen AR, Badrising UA. Detecting dysphagia in inclusion body myositis. J Neurol. 2009;256:2009–2013.CrossRef Cox FM, Verschuuren JJ, Verbist BM, Niks EH, Wintzen AR, Badrising UA. Detecting dysphagia in inclusion body myositis. J Neurol. 2009;256:2009–2013.CrossRef
5.
go back to reference Ko EH, Rubin AD. Dysphagia due to inclusion body myositis: case presentation and review of the literature. Ann Otol Rhinol Laryngol.. 2014;123:605–608.CrossRef Ko EH, Rubin AD. Dysphagia due to inclusion body myositis: case presentation and review of the literature. Ann Otol Rhinol Laryngol.. 2014;123:605–608.CrossRef
6.
go back to reference Mulcahy KP, Langdon PC, Mastaglia F. Dysphagia in inflammatory myopathy: self- report, incidence, and prevalence. Dysphagia. 2012;27:64–69.CrossRef Mulcahy KP, Langdon PC, Mastaglia F. Dysphagia in inflammatory myopathy: self- report, incidence, and prevalence. Dysphagia. 2012;27:64–69.CrossRef
7.
go back to reference Wintzen AR, Bots GT, de Bakker HM, Hulshof JH, Padberg GW. Dysphagia in inclusion body myositis. J Neurol Neurosurg Psychiatry. 1988;51:1542–1545.CrossRef Wintzen AR, Bots GT, de Bakker HM, Hulshof JH, Padberg GW. Dysphagia in inclusion body myositis. J Neurol Neurosurg Psychiatry. 1988;51:1542–1545.CrossRef
8.
go back to reference Oh TH, Brumfield KA, Hoskin TL, Stolp KA, Murray JA, Bassford JR. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc. 2007;82:441–447.CrossRef Oh TH, Brumfield KA, Hoskin TL, Stolp KA, Murray JA, Bassford JR. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc. 2007;82:441–447.CrossRef
9.
go back to reference Murata KY, Kouda K, Tajima F, Kondo T. A dysphagia study in patients with sporadic inclusion body myositis (s-IBM). Neurol Sci. 2012;33:765–770.CrossRef Murata KY, Kouda K, Tajima F, Kondo T. A dysphagia study in patients with sporadic inclusion body myositis (s-IBM). Neurol Sci. 2012;33:765–770.CrossRef
10.
go back to reference Mohannak N, Pattison G, Hird K, Needham M. Dysphagia in patients with sporadic inclusion body myositis: management challenges. Int J Gen Med.. 2019;12:465–474.CrossRef Mohannak N, Pattison G, Hird K, Needham M. Dysphagia in patients with sporadic inclusion body myositis: management challenges. Int J Gen Med.. 2019;12:465–474.CrossRef
11.
go back to reference Danon MJ, Friedman M. Inclusion body myositis associated with progressive dysphagia: treatment with cricopharyngeal myotomy. Can J Neurol Sci.. 1989;16:436–438.CrossRef Danon MJ, Friedman M. Inclusion body myositis associated with progressive dysphagia: treatment with cricopharyngeal myotomy. Can J Neurol Sci.. 1989;16:436–438.CrossRef
12.
go back to reference Olthoff A, Carstens PO, Zhang S, et al. Evaluation of dysphagia by novel real-time MRI. Neurology. 2016;87:2132–2138.CrossRef Olthoff A, Carstens PO, Zhang S, et al. Evaluation of dysphagia by novel real-time MRI. Neurology. 2016;87:2132–2138.CrossRef
13.
go back to reference Shibata S, Izumi R, Hara T, et al. Five-year history of dysphagia as a sole initial symptom in inclusion body myositis. J Neurol Sci.. 2017;381:325–327.CrossRef Shibata S, Izumi R, Hara T, et al. Five-year history of dysphagia as a sole initial symptom in inclusion body myositis. J Neurol Sci.. 2017;381:325–327.CrossRef
14.
go back to reference Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology. 2002;58:326.CrossRef Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology. 2002;58:326.CrossRef
15.
go back to reference Murata KY, Kouda K, Tajima F, Kondo T. Balloon dilation in sporadic inclusion body myositis patients with Dysphagia. Clin Med Insights Case Rep. 2013;6:1–7.CrossRef Murata KY, Kouda K, Tajima F, Kondo T. Balloon dilation in sporadic inclusion body myositis patients with Dysphagia. Clin Med Insights Case Rep. 2013;6:1–7.CrossRef
16.
go back to reference Jones K, Pitceathly RD, Rose MR, et al. Interventions for dysphagia in long-term, progressive muscle disease. Cochrane Database Syst Rev.. 2016;2:CD004303.PubMed Jones K, Pitceathly RD, Rose MR, et al. Interventions for dysphagia in long-term, progressive muscle disease. Cochrane Database Syst Rev.. 2016;2:CD004303.PubMed
17.
go back to reference Pars K, Garde N, Skripuletz T, Pul R, Dengler R, Stangel M. Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia. Muscle Nerve. 2013;48:838–839.CrossRef Pars K, Garde N, Skripuletz T, Pul R, Dengler R, Stangel M. Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia. Muscle Nerve. 2013;48:838–839.CrossRef
18.
go back to reference Cherin P, Delain JC, de Jaeger C, Crave JC. Subcutaneous immunoglobulin use in inclusion body myositis: a review of 6 cases. Case Rep Neurol. 2015;7:227–232.CrossRef Cherin P, Delain JC, de Jaeger C, Crave JC. Subcutaneous immunoglobulin use in inclusion body myositis: a review of 6 cases. Case Rep Neurol. 2015;7:227–232.CrossRef
19.
go back to reference Chandrasekhara V, Koh J, Lattimer L, Dunbar KB, Ravich WJ, Clarke JO. Endoscopic balloon catheter dilatation. World J Gastrointest Endosc. 2017;9:183–188.CrossRef Chandrasekhara V, Koh J, Lattimer L, Dunbar KB, Ravich WJ, Clarke JO. Endoscopic balloon catheter dilatation. World J Gastrointest Endosc. 2017;9:183–188.CrossRef
20.
go back to reference Marston AP, Maldonado FJ, Ravi K, Kasperbauer JL, Ekbom DC. Treatment of oropharyngeal dysphagia secondary to idiopathic cricopharyngeal bar: surgical cricopharyngeal muscle myotomy versus dilation. Am J Otolaryngol. 2016;37:507–512.CrossRef Marston AP, Maldonado FJ, Ravi K, Kasperbauer JL, Ekbom DC. Treatment of oropharyngeal dysphagia secondary to idiopathic cricopharyngeal bar: surgical cricopharyngeal muscle myotomy versus dilation. Am J Otolaryngol. 2016;37:507–512.CrossRef
21.
go back to reference Di Pede C, Masiero S, Bonsangue V, Ragona RM, Del Felice A. Botulinum toxin and rehabilitation treatment in inclusion body myositis for severe oropharyngeal dysphagia. Neurol Sci.. 2016;37:1743–1745.CrossRef Di Pede C, Masiero S, Bonsangue V, Ragona RM, Del Felice A. Botulinum toxin and rehabilitation treatment in inclusion body myositis for severe oropharyngeal dysphagia. Neurol Sci.. 2016;37:1743–1745.CrossRef
22.
go back to reference Liu LW, Tarnopolsky M, Armstrong D. Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis. Can J Gastroenterol. 2004;18:397–399.CrossRef Liu LW, Tarnopolsky M, Armstrong D. Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis. Can J Gastroenterol. 2004;18:397–399.CrossRef
23.
go back to reference Schrey A, Airas L, Jokela M, Pulkkinen J. Botulinum toxin alleviates dysphagia of patients with inclusion body myositis. J Neurol Sci. 2017;380:142–147.CrossRef Schrey A, Airas L, Jokela M, Pulkkinen J. Botulinum toxin alleviates dysphagia of patients with inclusion body myositis. J Neurol Sci. 2017;380:142–147.CrossRef
24.
go back to reference Naddaf E, Barohn RJ, Dimachkie MM. Inclusion body myositis: update on pathogenesis and treatment. Neurotherapeutics. 2018;15:995–1005.CrossRef Naddaf E, Barohn RJ, Dimachkie MM. Inclusion body myositis: update on pathogenesis and treatment. Neurotherapeutics. 2018;15:995–1005.CrossRef
Metadata
Title
Bar None: A Rare Cause of Oropharyngeal Dysphagia
Authors
Vaishnavi Boppana
Karen SantaCruz
Manish Shrestha
Nicholas Volpicelli
Denis McCarthy
Publication date
01-06-2020
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2020
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06274-7

Other articles of this Issue 6/2020

Digestive Diseases and Sciences 6/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine